Pet predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease

Journal of Nuclear Medicine

Volumn 43, Issue 8, 2002, Pages 1018-1027

  Kostakoglu, Lale ^a   Coleman, Morton ^a   Leonard, John P ^a   Kuji, Ichiei ^a   Zoe, Holly ^a   Goldsmith, Stanley J ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

18F FDG PET; Chemotherapy; Lymphoma; Posttherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; PREDNISONE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SCINTILLATION CAMERA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0036327331     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. The lymphomas
2. Prognostic factors in aggressive malignant lymphomas: Description and validation of prognostic index that could identify patients requiring a more intensive therapy
3. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management
4. Restaging laparotomy in the management of the non-Hodgkin lymphomas
5. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy
6. 67Ga scintigraphy after one cycle of chemotherapy
7. Single-photon emission computed tomography gallium imaging versus computed tomography: Predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma
8. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma
9. 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: A prospective pilot study
10. 67Ga scintigraphy
11. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in evaluation of lymphoma
12. Whole-body FDG PET imaging for staging of Hodgkin's disease and lymphoma
13. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
14. Extranodal malignant lymphoma: Detection with FDG PET versus CT
15. 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
16. 18-FDG PET for the assessment of residual masses on CT following treatment of lymphomas
17. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
18. 18F]FDG-PET a valid alternative to conventional diagnostic methods?
19. Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease?
20. High dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study
21. Comparison of a second generation combination chemotherapy regimen (mBACOP) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
22. 18F-FDG to detect residual disease after therapy for malignant lymphoma
23. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest
24. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment
25. Positron emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma: Comparison with clinico-radiologic assessment
26. The role of positron emission tomography (PET) in the management of lymphoma patients
27. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
28. F-18-FDG positron imaging in oncological patients: Gamma camera coincidence detection versus dedicated PET